US Stock MarketDetailed Quotes

NTLA Intellia Therapeutics

Watchlist
  • 15.620
  • +0.410+2.70%
Close Nov 29 13:00 ET
  • 15.600
  • -0.020-0.13%
Post 16:40 ET
1.59BMarket Cap-2866P/E (TTM)

Intellia Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
16.32%-84.84M
35.58%-58.19M
-10.37%-120.66M
-18.24%-394.09M
-3.54%-93.05M
-29.11%-101.38M
-6.15%-90.32M
-37.00%-109.33M
-48.11%-333.29M
-64.44%-89.87M
Net income from continuing operations
-11.04%-135.71M
-18.83%-146.98M
-4.18%-107.44M
-1.48%-481.19M
-16.54%-132.16M
-7.94%-122.22M
-22.85%-123.68M
29.79%-103.13M
-77.01%-474.19M
-39.60%-113.41M
Operating gains losses
----
----
----
43.86%15.71M
47.63%4.8M
130.08%3.85M
23.46%4.02M
11.04%3.05M
723.92%10.92M
--3.25M
Depreciation and amortization
13.89%2.61M
19.77%2.6M
22.54%2.51M
18.54%8.98M
21.42%2.47M
17.44%2.29M
18.13%2.17M
16.88%2.05M
9.88%7.57M
8.03%2.03M
Other non cash items
--0
--0
-820.02%-20.97M
-91.69%6.72M
--0
-90.94%968K
6.44%2.84M
-95.08%2.91M
2,653.83%80.88M
--8.3M
Change In working capital
172.61%9.94M
695.46%29.62M
19.43%-29.73M
2.64%-52.45M
123.18%3.11M
-142.66%-13.69M
71.15%-4.98M
-110.02%-36.9M
-135.21%-53.87M
-513.02%-13.42M
-Change in receivables
342.26%3.47M
16,059.60%24.1M
102.55%29K
-1,781.87%-32.69M
-11,850.98%-29.97M
-22.77%-1.43M
85.67%-151K
-594.78%-1.14M
-1,854.55%-1.74M
-44.57%255K
-Change in prepaid assets
289.98%10.88M
298.50%2.51M
-81.64%-8.75M
-1,157.78%-27.17M
-695.13%-15.36M
-765.26%-5.73M
-10,625.00%-1.26M
-1,241.00%-4.82M
77.95%-2.16M
59.11%-1.93M
-Change in payables and accrued expense
-63.17%667K
-27.93%7.2M
-3.77%-16.83M
-24.64%8.55M
239.43%12.97M
-84.84%1.81M
1,619.63%9.98M
-329.84%-16.22M
-36.25%11.34M
-81.65%3.82M
-Change in other current assets
14.00%5.06M
25.54%5.78M
33.06%5.68M
52.15%18.3M
11.03%4.99M
49.66%4.44M
63.70%4.61M
143.30%4.27M
27.09%12.03M
52.25%4.5M
-Change in other current liabilities
-16.92%-4.67M
-20.33%-4.57M
-1.43%-4.48M
-68.67%-16.67M
-33.58%-4.46M
-91.29%-4M
-68.46%-3.8M
-100.54%-4.42M
-8.53%-9.88M
-75.62%-3.34M
-Change in other working capital
37.70%-5.47M
62.45%-5.39M
63.15%-5.37M
95.62%-2.78M
308.83%34.93M
47.20%-8.79M
10.87%-14.35M
-4.08%-14.57M
-102.40%-63.46M
-16.40%-16.73M
Cash from discontinued investing activities
Operating cash flow
16.32%-84.84M
35.58%-58.19M
-10.37%-120.66M
-18.24%-394.09M
-3.54%-93.05M
-29.11%-101.38M
-6.15%-90.32M
-37.00%-109.33M
-48.11%-333.29M
-64.44%-89.87M
Investing cash flow
Cash flow from continuing investing activities
-109.70%-7.71M
29.96%-24.19M
104.83%5.9M
-119.55%-31.35M
252.36%45.94M
66.87%79.5M
-136.22%-34.54M
-357.51%-122.25M
129.11%160.31M
81.05%-30.15M
Net PPE purchase and sale
70.48%-1.28M
76.47%-1.01M
34.60%-2.51M
-4.30%-13.99M
61.15%-1.52M
-5.99%-4.33M
-8.07%-4.3M
-168.16%-3.83M
-5.11%-13.41M
-36.40%-3.91M
Net intangibles purchase and sale
----
----
----
--0
----
----
----
----
---44.83M
--0
Net business purchase and sale
----
----
----
--0
----
----
----
----
--0
----
Net investment purchase and sale
-107.67%-6.43M
23.35%-23.18M
107.10%8.41M
-107.94%-17.36M
280.87%47.46M
62.06%83.83M
-130.44%-30.24M
-226.33%-118.42M
140.85%218.55M
82.88%-26.24M
Cash from discontinued investing activities
Investing cash flow
-109.70%-7.71M
29.96%-24.19M
104.83%5.9M
-119.55%-31.35M
252.36%45.94M
66.87%79.5M
-136.22%-34.54M
-357.51%-122.25M
129.11%160.31M
81.05%-30.15M
Financing cash flow
Cash flow from continuing financing activities
330.28%82.19M
1,539.35%41.25M
2,601.13%59.99M
-77.64%130.32M
-78.95%106.48M
-20.33%19.1M
-57.32%2.52M
-95.31%2.22M
-20.87%582.96M
22,082.59%505.76M
Net common stock issuance
446.93%80.5M
--38.4M
3,858.66%58.03M
-78.83%119.8M
-79.43%103.61M
-36.71%14.72M
--0
-96.23%1.47M
-18.42%565.79M
--503.65M
Proceeds from stock option exercised by employees
-61.34%1.7M
13.20%2.85M
159.34%1.96M
-38.67%10.53M
35.90%2.87M
507.20%4.38M
-57.32%2.52M
-91.05%755K
-60.19%17.17M
-7.28%2.11M
Cash from discontinued financing activities
Financing cash flow
330.28%82.19M
1,539.35%41.25M
2,601.13%59.99M
-77.64%130.32M
-78.95%106.48M
-20.33%19.1M
-57.32%2.52M
-95.31%2.22M
-20.87%582.96M
22,082.59%505.76M
Net cash flow
Beginning cash position
-21.39%144.45M
-39.37%185.58M
-55.11%240.35M
326.71%535.46M
20.88%180.98M
17.33%183.76M
117.90%306.11M
326.71%535.46M
-23.77%125.49M
-55.57%149.72M
Current changes in cash
-272.58%-10.35M
66.38%-41.13M
76.12%-54.77M
-171.98%-295.11M
-84.61%59.37M
59.76%-2.78M
-857.60%-122.35M
-1,629.85%-229.36M
1,148.00%409.98M
282.40%385.74M
End cash Position
-25.91%134.1M
-21.39%144.45M
-39.37%185.58M
-55.11%240.35M
-55.11%240.35M
20.88%180.98M
17.33%183.76M
117.90%306.11M
326.71%535.46M
326.71%535.46M
Free cash flow
18.54%-86.12M
37.44%-59.2M
-8.84%-123.17M
-4.19%-408.07M
-0.85%-94.57M
-27.73%-105.71M
-6.23%-94.62M
10.23%-113.16M
-64.72%-391.68M
-63.04%-93.78M
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 16.32%-84.84M35.58%-58.19M-10.37%-120.66M-18.24%-394.09M-3.54%-93.05M-29.11%-101.38M-6.15%-90.32M-37.00%-109.33M-48.11%-333.29M-64.44%-89.87M
Net income from continuing operations -11.04%-135.71M-18.83%-146.98M-4.18%-107.44M-1.48%-481.19M-16.54%-132.16M-7.94%-122.22M-22.85%-123.68M29.79%-103.13M-77.01%-474.19M-39.60%-113.41M
Operating gains losses ------------43.86%15.71M47.63%4.8M130.08%3.85M23.46%4.02M11.04%3.05M723.92%10.92M--3.25M
Depreciation and amortization 13.89%2.61M19.77%2.6M22.54%2.51M18.54%8.98M21.42%2.47M17.44%2.29M18.13%2.17M16.88%2.05M9.88%7.57M8.03%2.03M
Other non cash items --0--0-820.02%-20.97M-91.69%6.72M--0-90.94%968K6.44%2.84M-95.08%2.91M2,653.83%80.88M--8.3M
Change In working capital 172.61%9.94M695.46%29.62M19.43%-29.73M2.64%-52.45M123.18%3.11M-142.66%-13.69M71.15%-4.98M-110.02%-36.9M-135.21%-53.87M-513.02%-13.42M
-Change in receivables 342.26%3.47M16,059.60%24.1M102.55%29K-1,781.87%-32.69M-11,850.98%-29.97M-22.77%-1.43M85.67%-151K-594.78%-1.14M-1,854.55%-1.74M-44.57%255K
-Change in prepaid assets 289.98%10.88M298.50%2.51M-81.64%-8.75M-1,157.78%-27.17M-695.13%-15.36M-765.26%-5.73M-10,625.00%-1.26M-1,241.00%-4.82M77.95%-2.16M59.11%-1.93M
-Change in payables and accrued expense -63.17%667K-27.93%7.2M-3.77%-16.83M-24.64%8.55M239.43%12.97M-84.84%1.81M1,619.63%9.98M-329.84%-16.22M-36.25%11.34M-81.65%3.82M
-Change in other current assets 14.00%5.06M25.54%5.78M33.06%5.68M52.15%18.3M11.03%4.99M49.66%4.44M63.70%4.61M143.30%4.27M27.09%12.03M52.25%4.5M
-Change in other current liabilities -16.92%-4.67M-20.33%-4.57M-1.43%-4.48M-68.67%-16.67M-33.58%-4.46M-91.29%-4M-68.46%-3.8M-100.54%-4.42M-8.53%-9.88M-75.62%-3.34M
-Change in other working capital 37.70%-5.47M62.45%-5.39M63.15%-5.37M95.62%-2.78M308.83%34.93M47.20%-8.79M10.87%-14.35M-4.08%-14.57M-102.40%-63.46M-16.40%-16.73M
Cash from discontinued investing activities
Operating cash flow 16.32%-84.84M35.58%-58.19M-10.37%-120.66M-18.24%-394.09M-3.54%-93.05M-29.11%-101.38M-6.15%-90.32M-37.00%-109.33M-48.11%-333.29M-64.44%-89.87M
Investing cash flow
Cash flow from continuing investing activities -109.70%-7.71M29.96%-24.19M104.83%5.9M-119.55%-31.35M252.36%45.94M66.87%79.5M-136.22%-34.54M-357.51%-122.25M129.11%160.31M81.05%-30.15M
Net PPE purchase and sale 70.48%-1.28M76.47%-1.01M34.60%-2.51M-4.30%-13.99M61.15%-1.52M-5.99%-4.33M-8.07%-4.3M-168.16%-3.83M-5.11%-13.41M-36.40%-3.91M
Net intangibles purchase and sale --------------0-------------------44.83M--0
Net business purchase and sale --------------0------------------0----
Net investment purchase and sale -107.67%-6.43M23.35%-23.18M107.10%8.41M-107.94%-17.36M280.87%47.46M62.06%83.83M-130.44%-30.24M-226.33%-118.42M140.85%218.55M82.88%-26.24M
Cash from discontinued investing activities
Investing cash flow -109.70%-7.71M29.96%-24.19M104.83%5.9M-119.55%-31.35M252.36%45.94M66.87%79.5M-136.22%-34.54M-357.51%-122.25M129.11%160.31M81.05%-30.15M
Financing cash flow
Cash flow from continuing financing activities 330.28%82.19M1,539.35%41.25M2,601.13%59.99M-77.64%130.32M-78.95%106.48M-20.33%19.1M-57.32%2.52M-95.31%2.22M-20.87%582.96M22,082.59%505.76M
Net common stock issuance 446.93%80.5M--38.4M3,858.66%58.03M-78.83%119.8M-79.43%103.61M-36.71%14.72M--0-96.23%1.47M-18.42%565.79M--503.65M
Proceeds from stock option exercised by employees -61.34%1.7M13.20%2.85M159.34%1.96M-38.67%10.53M35.90%2.87M507.20%4.38M-57.32%2.52M-91.05%755K-60.19%17.17M-7.28%2.11M
Cash from discontinued financing activities
Financing cash flow 330.28%82.19M1,539.35%41.25M2,601.13%59.99M-77.64%130.32M-78.95%106.48M-20.33%19.1M-57.32%2.52M-95.31%2.22M-20.87%582.96M22,082.59%505.76M
Net cash flow
Beginning cash position -21.39%144.45M-39.37%185.58M-55.11%240.35M326.71%535.46M20.88%180.98M17.33%183.76M117.90%306.11M326.71%535.46M-23.77%125.49M-55.57%149.72M
Current changes in cash -272.58%-10.35M66.38%-41.13M76.12%-54.77M-171.98%-295.11M-84.61%59.37M59.76%-2.78M-857.60%-122.35M-1,629.85%-229.36M1,148.00%409.98M282.40%385.74M
End cash Position -25.91%134.1M-21.39%144.45M-39.37%185.58M-55.11%240.35M-55.11%240.35M20.88%180.98M17.33%183.76M117.90%306.11M326.71%535.46M326.71%535.46M
Free cash flow 18.54%-86.12M37.44%-59.2M-8.84%-123.17M-4.19%-408.07M-0.85%-94.57M-27.73%-105.71M-6.23%-94.62M10.23%-113.16M-64.72%-391.68M-63.04%-93.78M
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme ARK Portfolio
ARK Portfolio
Intraday+2.57%
Gene Editing
Gene Editing
Intraday+0.54%